Celgene Corporation (United States) holds 0 active US FDA Type II Drug Master Files and 2 inactive, has DMF or CEP filings on record for 1 active ingredient and is linked to 1 FDA-registered manufacturing site. 24 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Celgene Corporation: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/celgene-corporation

Overview

Celgene Corporation, acquired by Bristol Myers Squibb in 2019, is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for unmet medical needs. Celgene specializes in treatments for cancer and inflammatory disorders.

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Celgene Corporation holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Celgene Corporation holds 0 active (2 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • MARIZOMIB, A LYOPHILIZED POWDER FOR INJECTION WITH ACCOMPANYING DILUENTInactive2018-05-04
  • FR901228Inactive1996-08-07

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to Celgene Corporation, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

24 FDA enforcement records linked to this company.

  • 4832024-12-06

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) A

  • 4832024-12-06

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) E

  • 4832024-12-06

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) B

  • 4832024-12-06

    Failure to comply with REMS Implementation System

  • 4832023-06-16

    Expiration date lacking

  • 4832023-06-16

    Absence of Written Procedures

  • 4832023-06-16

    Environmental Monitoring System

  • 4832023-06-16

    Mfg / Processing Operations Area

  • 4832013-04-24

    Failure to develop written procedures

  • 4832013-04-24

    Post marketing study status report for other studies

  • 4832013-04-24

    Late submission of 15-day report

  • 4832011-08-25

    Late submission of 15-day report

  • 4832011-08-25

    Post marketing study status report for other studies

  • 4832010-03-19

    Acceptance criteria for sampling & testing

  • 4832010-03-19

    Records reviewed annually

  • 4832010-03-19

    Procedure Deviations Recorded and Justified

  • 4832010-03-19

    Procedures not in writing, fully followed

  • 4832009-09-03

    Failure to review ADE information

  • 4832009-09-03

    Failure to separately submit original and follow-up reports

  • 4832009-09-03

    Failure to report non-alert ADEs

  • 4832009-09-03

    Late submission of 15-day report

  • 4832009-09-03

    Late submission of quarterly safety reports

  • 4832009-09-03

    Failure to develop written procedures

  • 4832009-08-14

    Complaint Investigation/Follow-Up Findings

For suppliers

Is this Celgene Corporation?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.